quinuclidines has been researched along with Kahler Disease in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Canale, FA; Console, G; Cusumano, G; Di Costanzo, A; Ferreri, A; Gallo, S; Gangemi, T; Irrera, G; Loddo, V; Loteta, B; Martino, M; Meliambro, N; Moscato, T; Naso, V; Paviglianiti, A; Porcino, D; Porto, G; Provenzano, PF; Pugliese, M; Romeo, V; Rossetti, AM; Russo, L | 1 |
| Sebestyén, Z; Szabó, B; Szepesi, K | 1 |
| Abhyankar, S; Aljitawi, OS; Deauna-Limayo, D; Ganguly, S; McGuirk, JP; Wick, JA | 1 |
| Chang, H; Jiang, H; Reece, D; Saha, MN; Yang, Y | 1 |
| Amiot, M; Descamps, G; Godon, C; Le Gouill, S; Lodé, L; Maïga, S; Marionneau-Lambot, S; Moreau, P; Oullier, T; Pellat-Deceunynck, C; Tessoulin, B | 1 |
| Abdi, J; Chang, H; Saha, MN; Yang, Y | 1 |
| Ishikawa, T; Isoda, A; Komatsu, F; Manaka, A; Matsumoto, M; Miyazawa, Y; Negishi, Y; Oosawa, N; Saito, R; Sawamura, M | 1 |
| Beveridge, R; Bubalo, JS; DeGroot, TJ; Giralt, SA; Hurd, DD; Mangan, KF; Maziarz, RT; Mendoza, FL; Rubenstein, EB; Schuster, MW | 1 |
1 review(s) available for quinuclidines and Kahler Disease
| Article | Year |
|---|---|
[Pharmaceutical applications of sulfobuthylether-beta-cyclodextrin].
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Antiemetics; Antifungal Agents; Antipsychotic Agents; Aripiprazole; beta-Cyclodextrins; Chemistry, Pharmaceutical; Dosage Forms; Drug Stability; Humans; Hungary; Multiple Myeloma; Oligopeptides; Piperazines; Pyrimidines; Quinolones; Quinuclidines; Solubility; Thiazoles; Triazoles; Voriconazole | 2013 |
2 trial(s) available for quinuclidines and Kahler Disease
| Article | Year |
|---|---|
Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: A phase II study.
Topics: Adult; Aged; Antiemetics; Aprepitant; Dexamethasone; Drug Therapy, Combination; Humans; Isoquinolines; Melphalan; Middle Aged; Morpholines; Multiple Myeloma; Myeloablative Agonists; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Transplantation, Autologous; Treatment Outcome | 2017 |
Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dexamethasone; Double-Blind Method; Female; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Male; Melphalan; Middle Aged; Multiple Myeloma; Nausea; Palonosetron; Quinuclidines; Vomiting | 2011 |
5 other study(ies) available for quinuclidines and Kahler Disease
| Article | Year |
|---|---|
Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience.
Topics: Antiemetics; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Multiple Myeloma; Nausea; Palonosetron; Pyridines; Quality of Life; Quinuclidines; Transplantation, Autologous; Vomiting | 2022 |
Combined use of multiday palonosetron with aprepitant and low-dose dexamethasone in prevention of nausea and emesis among patients with multiple myeloma and lymphoma undergoing autologous hematopoietic stem cell transplant: A pilot study.
Topics: Adult; Aged; Antiemetics; Aprepitant; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Lymphoma; Male; Middle Aged; Morpholines; Multiple Myeloma; Nausea; Palonosetron; Pilot Projects; Quality of Life; Quinuclidines; Transplantation, Autologous; Vomiting | 2014 |
PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aza Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Dexamethasone; DNA-Binding Proteins; Doxorubicin; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, SCID; Multiple Myeloma; Neoplasms, Experimental; Nuclear Proteins; Proto-Oncogene Proteins c-bcl-2; Quinuclidines; Tumor Protein p73; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2013 |
PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Death; Cells, Cultured; Female; Glutathione; Humans; Mice; Mice, SCID; Multiple Myeloma; Quinuclidines; Reactive Oxygen Species; Signal Transduction; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2014 |
MiRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Case-Control Studies; Cell Proliferation; Combined Modality Therapy; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Hematopoietic Stem Cells; Humans; Immunoenzyme Techniques; Mice; Mice, SCID; MicroRNAs; Multiple Myeloma; Proto-Oncogene Mas; Proto-Oncogene Proteins c-myc; Quinuclidines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |